Experienced in Riboflavin Transporter Deficiency Neuronopathy

Dr. Craig M. Zaidman

Pediatric Neurology | Neurology
Washington University
4455 Duncan Ave, 
Saint Louis, MO 
 (359.8 mi)
Accepting New Patients
Offers Telehealth
Experienced in Riboflavin Transporter Deficiency Neuronopathy
Washington University
4455 Duncan Ave, 
Saint Louis, MO 
 (359.8 mi)
OverviewInsuranceLocationsClinical Research

Overview

Craig Zaidman is a Pediatric Neurologist and a Neurologist in Saint Louis, Missouri. Dr. Zaidman and is rated as an Experienced provider by MediFind in the treatment of Riboflavin Transporter Deficiency Neuronopathy. His top areas of expertise are Becker Muscular Dystrophy, Duchenne Muscular Dystrophy, Spinal Muscular Atrophy (SMA), and Primary Lateral Sclerosis. Dr. Zaidman is currently accepting new patients.

His clinical research consists of co-authoring 76 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Riboflavin Transporter Deficiency Neuronopathy.

Specialties
Pediatric Neurology
Neurology
Licenses
Neurology with Special Qualifications in Neurology in MO
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Cox Health
  •  Humana

Locations

WASHINGTON UNIVERSITY
4455 Duncan Ave, Saint Louis, MO 63110
Other Locations
WASHINGTON UNIVERSITY
4921 Parkview Pl, Suite 6c, Saint Louis, MO 63110
WASHINGTON UNIVERSITY
1 Barnes Jew Hosp Plz, Saint Louis, MO 63110

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study with an Open-Label Extension to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Muscular Dystrophy
A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study with an Open-Label Extension to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Muscular Dystrophy
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2025
Intervention Type: Drug
Study Drug: Ifetroban
Study Phase: Phase 2
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARK)
Enrollment Status: Completed
Publish Date: December 10, 2024
Intervention Type: Genetic
Study Phase: Phase 3
An Open-Label, Systemic Gene Delivery Study Using Commercial Process Material to Evaluate the Safety of and Expression From SRP-9001 in Subjects With Duchenne Muscular Dystrophy (ENDEAVOR)
An Open-Label, Systemic Gene Delivery Study Using Commercial Process Material to Evaluate the Safety of and Expression From SRP-9001 in Subjects With Duchenne Muscular Dystrophy (ENDEAVOR)
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2024
Intervention Type: Genetic
Study Phase: Phase 1
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: August 26, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
Open Label, Long-term Safety, Tolerability, and Efficacy Study of GIVINOSTAT in All DMD Patients Who Have Been Previously Treated in One of the GIVINOSTAT Studies
Open Label, Long-term Safety, Tolerability, and Efficacy Study of GIVINOSTAT in All DMD Patients Who Have Been Previously Treated in One of the GIVINOSTAT Studies
Enrollment Status: Enrolling_by_invitation
Publish Date: November 07, 2023
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Enrollment Status: Terminated
Publish Date: April 24, 2023
Intervention Type: Biological
Study Phase: Phase 1
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: February 02, 2023
Intervention Type: Drug
Study Drug: Givinostat
Study Phase: Phase 3
A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2
Enrollment Status: Completed
Publish Date: September 07, 2022
Intervention Type: Biological
Study Drug: Onasemnogene Abeparvovec-Xioi
Study Phase: Phase 3
View 8 Less Clinical Trials

76 Total Publications

Safety and Efficacy of IV Onasemnogene Abeparvovec for Pediatric Patients With Spinal Muscular Atrophy: The Phase 3b SMART Study.
Safety and Efficacy of IV Onasemnogene Abeparvovec for Pediatric Patients With Spinal Muscular Atrophy: The Phase 3b SMART Study.
Journal: Neurology
Published: January 13, 2025
Similar Doctors
Experienced in Riboflavin Transporter Deficiency Neuronopathy
Dr. Paul T. Golumbek
Neurology | Pediatric Neurology
Experienced in Riboflavin Transporter Deficiency Neuronopathy
Dr. Paul T. Golumbek
Neurology | Pediatric Neurology
4921 Parkview Pl Ste 6c, Ste 6c, 
Saint Louis, MO 
 (0.3 mi)
314-362-4838
Languages Spoken:
English

Paul Golumbek is a Neurologist and a Pediatric Neurologist in Saint Louis, Missouri. Dr. Golumbek and is rated as an Experienced provider by MediFind in the treatment of Riboflavin Transporter Deficiency Neuronopathy. His top areas of expertise are Primary Lateral Sclerosis, Becker Muscular Dystrophy, Riboflavin Transporter Deficiency Neuronopathy, and Duchenne Muscular Dystrophy.

Experienced in Riboflavin Transporter Deficiency Neuronopathy
Dr. Yvonne D. Rollins
Neurology
Experienced in Riboflavin Transporter Deficiency Neuronopathy
Dr. Yvonne D. Rollins
Neurology

Salida Hospital District

550 W Us Hwy 50, 
Salida, CO 
 (42.4 mi)
719-530-2000
Languages Spoken:
English
See accepted insurances

Yvonne Rollins is a Neurologist in Salida, Colorado. Dr. Rollins and is rated as an Advanced provider by MediFind in the treatment of Riboflavin Transporter Deficiency Neuronopathy. Her top areas of expertise are Chronic Inflammatory Demyelinating Polyneuropathy, Benign Rolandic Epilepsy, Memory Loss, and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease).

Experienced in Riboflavin Transporter Deficiency Neuronopathy
Dr. Timothy M. Miller
Neurology
Experienced in Riboflavin Transporter Deficiency Neuronopathy
Dr. Timothy M. Miller
Neurology

Washington University

4921 Parkview Pl, Suite 6c, 
Saint Louis, MO 
 (0.2 mi)
314-362-1408
Languages Spoken:
English, French
See accepted insurances
Accepting New Patients
Offers Telehealth

Timothy Miller is a Neurologist in Saint Louis, Missouri. Dr. Miller and is rated as an Advanced provider by MediFind in the treatment of Riboflavin Transporter Deficiency Neuronopathy. His top areas of expertise are Spinal and Bulbar Muscular Atrophy, Spinal Muscular Atrophy (SMA), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), and Spinal Muscular Atrophy Type 3. Dr. Miller is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile